Abstract
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Keywords: Disease-modifying drugs, PPAR, stroke.
Current Drug Targets
Title:PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Volume: 14 Issue: 7
Author(s): Thavarak Ouk, Camille Potey, Sophie Gautier, Michele Bastide, Dominique Deplanque, Bart Staels, Patrick Duriez, Didier Leys and Regis Bordet
Affiliation:
Keywords: Disease-modifying drugs, PPAR, stroke.
Abstract: Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Export Options
About this article
Cite this article as:
Ouk Thavarak, Potey Camille, Gautier Sophie, Bastide Michele, Deplanque Dominique, Staels Bart, Duriez Patrick, Leys Didier and Bordet Regis, PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070005
DOI https://dx.doi.org/10.2174/1389450111314070005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Plasma Retinol Binding Protein 4 as a Biomarker for Detecting Progressive Stroke and Prediction of Early Prognosis in Patients with Acute Ischemic Stroke
Current Neurovascular Research Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Does Perioperative Hemoglobin A1c Level Affect the Incidence, Pattern and Mortality of Lower Extremity Amputation?
Current Vascular Pharmacology Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Central Nervous System Agents in Medicinal Chemistry Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates
Current Medicinal Chemistry Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Genetics of Serotonin Receptors and Depression: State of the Art
Current Drug Targets Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Hot Topic :Incretins: Novel Cardiovascular Protection Agents)
Cardiovascular & Hematological Agents in Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy The Therapeutic Activities of Metformin: Focus on the Nrf2 Signaling Pathway and Oxidative Stress Amelioration
Current Molecular Pharmacology Fatty Acids Recommendations: Controversies and Updates
Current Nutrition & Food Science HspB8 is Neuroprotective during Oxygen Glucose Deprivation and Reperfusion
Current Neurovascular Research